PNC Financial Services Group
RAPP

PNC Financial Services Group’s Rapport Therapeutics RAPP Stock Holding History

PNC Financial Services Group’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.5K Buy
48
+1
+2% +$28 ﹤0.01% 4664
2025
Q4 		$1.43K Sell
47
-5
-10% -$138 ﹤0.01% 4608
2025
Q3 		$1.54K Buy
+52
New +$928 ﹤0.01% 4570

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $401M AUM 284.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

PNC Financial Services Group's RAPP Position: Q1 2026 in Review

PNC Financial Services Group increased its Rapport Therapeutics (RAPP) stake by 2.1% in Q1 2026, buying an estimated $28 and bringing the position to 48 shares worth $1.5K. The position accounts for ﹤0.01% of the portfolio, ranked #4664.

PNC Financial Services Group first reported a position in RAPP in Q3 2025 and has held it in 3 quarters since. The position peaked at $1.54K in Q3 2025. 147 funds tracked by Wall St. Rank hold RAPP as of Q1 2026.

  • PNC Financial Services Group held 48 shares of Rapport Therapeutics worth $1.5K as of Q1 2026.
  • PNC Financial Services Group bought 1 Rapport Therapeutics share in Q1 2026, an estimated $28.
  • Rapport Therapeutics made up ﹤0.01% of PNC Financial Services Group's portfolio in Q1 2026, its #4664 holding.
  • PNC Financial Services Group first reported a position in Rapport Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • PNC Financial Services Group's Rapport Therapeutics position peaked at $1.54K in Q3 2025.
  • 147 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q1 2026.

Based on PNC Financial Services Group's 13F filing for Q1 2026, filed 8 May 2026.